Ignite Creation Date:
2025-12-24 @ 11:37 PM
Ignite Modification Date:
2025-12-28 @ 6:24 PM
Study NCT ID:
NCT06143956
Status:
RECRUITING
Last Update Posted:
2025-12-23
First Post:
2023-11-06
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
Sponsor:
Eli Lilly and Company
Organization:
Study Overview
Official Title:
A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Interventions for Chronic Weight Management in Adult Participants With Obesity or Overweight
Status:
RECRUITING
Status Verified Date:
2025-12
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this Phase-2 chronic weight management master protocol (CWMM) is to create a framework to evaluate the safety and efficacy of various investigational interventions for chronic weight management with intervention-specific appendices (ISAs). The CWMM establishes entry criteria for newly enrolled participants across the master and the ISAs. The ISAs may start independently of other ISAs as interventions become available for clinical testing. The results for the CWMM screening record will be reported when all the ISA's complete.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| W8M-MC-CWMM | OTHER | Eli Lilly and Company | View | |
| W8M-MC-OXA1 | OTHER | Eli Lilly and Company | View | |
| W8M-MC-LAA1 | OTHER | Eli Lilly and Company | View | |
| W8M-MC-LAA2 | OTHER | Eli Lilly and Company | View | |
| W8M-MC-GN01 | OTHER | Eli Lilly and Company | View | |
| W8M-MC-GN02 | OTHER | Eli Lilly and Company | View |